daptomycin (cubicin) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms. Daptomycin has a distinct mechanism of action, disrupting multiple aspects of bacterial cell membrane function. It inserts into the cell membrane in a phosphatidylglycerol-dependent fashion, where it then aggregates. The aggregation of daptomycin alters the curvature of the membrane, which creates holes that leak ions. This causes rapid depolarization, resulting in a loss of membrane potential leading to inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death. Daptomycin is bactericidal against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant enterococci (GRE)), staphylococci (including methicillin-resistant Staphylococcus aureus), streptococci, corynebacteria and stationary-phase Borrelia burgdorferi persisters.   NCATS

Chemistry

  • SMILES: CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=C(N)C=CC=C4)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O
  • InChIKey: DOAKLVKFURWEDJ-QCMAZARJSA-N
  • Mol. Mass: 1620.6706
  • ALogP: Missing data
  • ChEMBL Molecule:
    daptomycin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$25.1300 - $159.8400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

cidecin | cubicin | dapcin | daptomicina | daptomycin | daptomycine | daptomycinum | deptomycin | ly146032 | ly-146032

Organizations (92)

Research & Development (68)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (25)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (58)

Approved Indications (3)


 

Infections

Staphylococcal Skin Infections (approved 2003)

Staphylococcus aureus (approved 2003)

Experimental Indications - Clinical Trial Phases 1-4 (58)


 

Abscess (Phase 4)

Anti-Bacterial Agents (Phase 1)

Antibiotic Prophylaxis (Phase 1)

Arthritis, Infectious (Phase 4)

Ascites (Phase 2/Phase 3)

Bacteremia (Phase 4)

Bacterial Infections (Phase 4)

Burns (Phase 4)

Catheter-Related Infections (Phase 4)

Cellulitis (Phase 4)

Central Nervous System Infections (Phase 4)

Critical Care (Phase 3)

Critical Illness (Phase 4)

Cross Infection (Phase 3)

Daptomycin (Phase 1)

Dermatology (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetic Foot (Phase 4)

Drug Interactions (Early Phase 1)

Endocarditis (Phase 4)

Endocarditis, Bacterial (Phase 4)

Febrile Neutropenia (Phase 3)

Fever (Phase 2)

Fibrosis (Phase 2/Phase 3)

General Surgery (Phase 3)

Gram-Positive Bacteria (Phase 3)

Gram-Positive Bacterial Infections (Phase 3)

Healthcare-Associated Pneumonia (Phase 4)

Healthy Volunteers (Phase 1)

Hot Flashes (Phase 2)

Infections ()

Injections, Subcutaneous (Phase 1)

Kidney Diseases (Phase 1/Phase 2)

Kidney Failure, Chronic (Phase 4)

Lymphoma (Phase 2)

Meningitis (Phase 1)

Meningitis, Pneumococcal (Phase 2)

Methicillin-Resistant Staphylococcus aureus (Phase 4)

Neoplasms (Phase 2)

Neutropenia (Phase 2)

Osteoarthritis (Phase 4)

Osteomyelitis (Phase 4)

Peritonitis (Phase 2/Phase 3)

Pharmacokinetics (Early Phase 1)

Pneumonia, Bacterial (Phase 3)

Prosthesis-Related Infections (Phase 2)

Renal Dialysis (Phase 4)

Renal Insufficiency (Phase 3)

Sepsis (Phase 2)

Skin Diseases (Phase 3)

Skin Diseases, Infectious (Phase 4)

Soft Tissue Infections (Phase 4)

Staphylococcal Infections (Phase 4)

Staphylococcal Skin Infections (Phase 4)

Staphylococcus aureus (Phase 4)

Surgical Wound Infection (Phase 3)

Sweating (Phase 2)

Wound Infection (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 81
  • # of Trial Organizations: 68

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue